Genetic variations in toll-like receptor pathway and lung function decline in Cystic Fibrosis patients

Human Immunology

Volumn 74, Issue 12, 2013, Pages 1649-1655

  Haerynck, F ^a   Mahachie John, J M ^b   Van Steen, K ^a,b   Schelstraete, P ^a   Van daele, S ^a   Loeys, B ^c   Van Thielen, M ^d   De Canck, I ^d   Nuytinck, L ^e   De Baets, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d INNOGENETICS   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CODOMINANCE; CYSTIC FIBROSIS; DETERIORATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

CF; CYSTIC FIBROSIS; FEV1; FORCED EXPIRATORY VOLUME IN ONE SECOND; LBP; LIPOPOLYSACCHARIDE BINDING PROTEIN; NFΚB; NUCLEAR FACTOR KAPPA BETA; PA; PSEUDOMONAS AERUGINOSA; SINGLE NUCLEOTIDE POLYMORPHISMS; SNP; TLR; TOLL-LIKE RECEPTOR;

ADOLESCENT; ADULT; ALLELES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; YOUNG ADULT;

EID: 84888200516     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.08.282     Document Type: Article

References (42)

1. Collaco J.M., Cutting G.R. Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med 2008, 14:559.
2. Corvol H., Fitting C., Chadelat K., Jacquot J., Tabary O., Boule Met, et al. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol. Lung Cellular Mol Physiol 2003, 284:L997.
3. Chmiel J.F., Davis P.B. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?. Respir Res 2003, 4:8.
4. Bodas M., Vij N. The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov Med 2010, 9:346.
5. Greene C.M., Ramsay H., Wells R.J., O'Neill S.J., McElvaney N.G. Inhibition of Toll-like receptor 2-mediated interleukin-8 production in Cystic Fibrosis airway epithelial cells via the alpha7-nicotinic acetylcholine receptor. Mediators Inflamm 2010, 2010:423241.
6. Corvol H., Boelle P.Y., Brouard J., Knauer N., Chadelat K., Henrion-Caude Aet, et al. Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatric Pulmonol 2008, 43:1224.
7. Parker D., Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 2011, 45:189.
8. Koller B., Bals R., Roos D., Korting H.C., Griese M., Hartl D. Innate immune receptors on neutrophils and their role in chronic lung disease. Eur J Clin Invest 2009, 39:535.
9. Urquhart D.S., Allen J., Elrayess M., Fidler K., Klein N., Jaffe A. Modifier effect of the Toll-like receptor 4 D299G polymorphism in children with cystic fibrosis. Archivum Immunologiae et Therapiae Experimentalis 2006, 54:271.
10. Netea M.G., van der Graaf C., Van der Meer J.W., Kullberg B.J. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukocyte Biol 2004, 75:749.
11. Netea M.G., Van der Meer J.W., Kullberg B.J. Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol 2004, 12:484.
12. Albiger B., Dahlberg S., Henriques-Normark B., Normark S. Role of the innate immune system in host defence against bacterial infections: focus on the Toll-like receptors. J Intern Med 2007, 261:511.
13. Schroder N.W., Schumann R.R. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005, 5:156.
14. Dalgic N., Tekin D., Kayaalti Z., Soylemezoglu T., Cakir E., Kilic Bet, et al. Arg753Gln polymorphism of the human Toll-like receptor 2 gene from infection to disease in pediatric tuberculosis. Hum Immunol 2011, 72:440.
15. Doring G., Conway S.P., Heijerman H.G., Hodson M.E., Hoiby N. Smyth Aet al.: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Resp J: Offic J Eur Soc Clin Resp Physiol 2000, 16:749.
16. Stanojevic S., Wade A., Stocks J., Hankinson J., Coates A.L. Pan Het al.: Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008, 177:253.
17. Quanjer P.H., Borsboom G.J., Kivastik J., Merkus P.J., Hankinson J.L., Houthuijs Det, et al. Cross-sectional and longitudinal spirometry in children and adolescents: interpretative strategies. Am J Respir Crit Care Med 2008, 178:1262.
18. Verstraelen H., Verhelst R., Nuytinck L., Roelens K., De Meester E., De Vos Det, et al. Gene polymorphisms of Toll-like and related recognition receptors in relation to the vaginal carriage of Gardnerella vaginalis and Atopobium vaginae. J Reprod Immunol 2009, 79:163.
19. Vander Cruyssen B., Nuytinck L., Boullart L., Elewaut D., Waegeman W., Van Thielen M., et al. Polymorphisms in the ficolin 1 gene (FCN1) are associated with susceptibility to the development of rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1792.
20. Cedzynski M., Nuytinck L., Atkinson A.P., Swierzko A., Zeman K., Szemraj Jet, et al. Extremes of L-ficolin concentration in children with recurrent infections are associated with single nucleotide polymorphisms in the FCN2 gene. Clin Exp Immunol 2007, 150:99.
21. Stuyver L., Rossau R., Wyseur A., Duhamel M., Vanderborght B., Van Heuverswyn H., et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J General Virol 1993, 74:1093.
22. Haerynck F., Van Steen K., Cattaert T., Loeys B., Van Daele S., Schelstraete Pet, et al. Polymorphisms in the lectin pathway genes as a possible cause of early chronic Pseudomonas aeruginosa colonization in cystic fibrosis patients. Hum Immunol 2012, 73:1175.
23. Johnson A.D., Handsaker R.E., Pulit S.L., Nizzari M.M., O'Donnell C.J., de Bakker P.I. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008, 24:2938.
24. Guedj M., Nuel G., Prum B. A note on allelic tests in case-control association studies. Ann Hum Genet 2008, 72:407.
25. Knapp M. On the asymptotic equivalence of allelic and trend statistic under Hardy-Weinberg equilibrium. Ann Hum Genet 2008, 72:589.
26. Yarden J., Radojkovic D., De Boeck K., Macek M., Zemkova D., Vavrova V., et al. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 2005, 60:320.
27. Levy H., Murphy A., Zou F., Gerard C., Klanderman B., Schuemann B., et al. IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatric Pulmonol 2009, 44:580.
28. Tesse R., Cardinale F., Santostasi T., Polizzi A., Manca A., Mappa L., et al. Association of beta-defensin-1 gene polymorphisms with Pseudomonas aeruginosa airway colonization in cystic fibrosis. Genes Immun 2008, 9:57.
29. Park J.E., Yung R., Stefanowicz D., Shumansky K., Akhabir L., Durie P.R., et al. Cystic fibrosis modifier genes related to Pseudomonas aeruginosa infection. Genes Immun 2011, 12:370.
30. Drumm M.L., Konstan M.W., Schluchter M.D., Handler A., Pace R., Zou F., et al. Genetic modifiers of lung disease in cystic fibrosis. New Eng J Med 2005, 353:1443.
31. Dorfman R., Sandford A., Taylor C., Huang B., Frangolias D. Wang Yet al.: Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008, 118:1040.
32. Davies J.C., Griesenbach U., Alton E. Modifier genes in cystic fibrosis. Pediatr Pulmonol 2005, 39:383.
33. Blohmke C.J., Park J., Hirschfeld A.F., Victor R.E., Schneiderman J. Stefanowicz Det al.: TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. J Immunol 2010, 185:7731.
34. Koller B., Bals R., Roos D., Korting H.C., Griese M., Hartl D. Innate immune receptors on neutrophils and their role in chronic lung disease. Eur J Clin Invest 2009, 39:535.
35. Rohmann K., Tschernig T., Pabst R., Goldmann T., Dromann D. Innate immunity in the human lung: pathogen recognition and lung disease. Cell Tissue Res 2011, 343:167.
36. Jiang D., Liang J., Fan J., Yu S., Chen S., Luo Y., et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005, 11:1173.
37. Volkova M., Zhang Y.T., Shaw A.C., Lee P.J. The role of toll-like receptors in age-associated lung diseases. J Gerontol Series a-Biol Sci Med Sci 2012, 67:247.
38. Lorenz E., Mira J.P., Cornish K.L., Arbour N.C., Schwartz D.A. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000, 68:6398.
39. Shuto T., Furuta T., Oba M., Xu H., Li J.D., Cheung J., et al. Promoter hypomethylation of Toll-like receptor-2 gene is associated with increased proinflammatory response toward bacterial peptidoglycan in cystic fibrosis bronchial epithelial cells. FASEB J: Offic Publication Fed Am Soc Exper Biol 2006, 20:782.
40. Takeuchi O., Sato S., Horiuchi T., Hoshino K., Takeda K., Dong Z., et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002, 169:10.
41. Wurfel M.M., Gordon A.C., Holden T.D., Radella F., Strout J., Kajikawa O., et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Res Critic Care Med 2008, 178:710.
42. Blohmke C.J., Victor R.E., Hirschfeld A.F., Elias I.M., Hancock D.G., Lane C.R., et al. Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J Immunol 2008, 180:7764.